Hep B Blog

Monthly Archives: April 2026

Uncategorized

What to Know About the New B‑SUPREME Study for Chronic Hepatitis B

 

 

 

 

 

 

 

 

 

Many people living with chronic hepatitis B are hoping for better treatment options, especially medicines that can lead to long-lasting control of the virus. A new research study, called B‑SUPREME, is now enrolling participants to help test a potential new treatment. This study could play an important role in moving HBV research forward.

What Is the B‑SUPREME Study?
B‑SUPREME is a Phase 2 clinical trial. Phase 2 studies focus on learning more about how safe a medicine is and how well it works. The medicine being tested is called ALG‑000184. It is considered investigational, which means it is approved for use in clinical research but is not yet approved for the treatment of chronic hepatitis B infection.

Researchers want to understand how well this study medicine lowers the hepatitis B virus in the blood and how safe the study medicine may be.

Who Can Join the Study?
The study has a few main requirements. Participants must:

  • Be between 18 and 65 years old with a diagnosis of chronic hepatitis B infection,
  • Have either never received hepatitis B treatment or must not have received hepatitis
    B treatment within the last six months before enrolling in the study and
  • Have never received a capsid assembly modulator (CAM), since previous exposure
    could affect study results.

What Does Participation Involve?
If someone qualifies and chooses to join, the entire study lasts about 28 months. That’s a little more than two years. The time is divided into several phases so researchers can understand the medicine from different angles.

The First 48 Weeks
During the first part of the study, participants are randomly assigned to receive either the new study drug, ALG‑000184, or a placebo version of TDF. A placebo looks exactly like real medicine but does not contain any active drug. TDF is a standard treatment for hepatitis B. Using a placebo version helps researchers compare how well the new study drug works.

Everyone takes one pill per day. For the first four weeks, you will visit the study center every two weeks. After that, visits happen once every four weeks until Week 48.

The Next 48 Weeks: Extension Phase
During an extension period of 48 weeks all study participants will take ALG‑000184 only. This part of the study is designed to help researchers learn more about how the medicine works inside the body and how strong its antiviral effects may be.

During this phase, participants return every six to eight weeks until they reach Week 96.

The Long-Term Follow-Up Option
Once participants finish Week 96, they can choose what to do next. One option is to join a long-term follow-up study. This would allow them to continue taking ALG‑000184 for another three to four years. This extra time helps researchers study medicine’s long-term safety and efficacy.

If someone decides not to continue, that is completely fine. They would have just one final visit at eight weeks after taking their last dose.

Costs, Care, and Support
All study-related medication and tests are free for participants. They will also receive reimbursement for travel/transportation. People can leave the study at any time. If participants experience any study-related side effects, the study team will take good care
of them.

If a participant agrees, their treating doctor can also stay informed of their progress, which helps ensure that the person receives support if they decide to leave.

Why This Study Matters
Current treatments help many people but they do not work the same for everyone. Some people may still have virus in their body. The B‑SUPREME study explores whether the study medication could be a future treatment option for chronic hepatitis B. By taking part in the study, participants may help improve understanding of hepatitis B and support future research and care for themselves and others.

300 Million Reasons, About Hepatitis B, HBV, Liver, Liver Cancer, Liver Health, Living with Hepatitis B

Coping With Anxiety Around Liver Cancer Monitoring

 

 

 

 

 

 

 

 

 

For people living with chronic hepatitis B, regular testing is an important part of staying healthy. Blood tests and imaging, such as ultrasounds, help doctors monitor the individual patient’s health and the effectiveness of whatever medications they may be taking and even find liver cancer early, which increases the effectiveness of treatment. Even so, many people feel anxious about monitoring. It is common to worry before appointments or feel stressed while waiting for results. Research shows that this kind of anxiety is very common among people living with hepatitis B (Low et al., 2025). 

The good news is that there are strategies and ways to help reduce the anxiety associated with screening and monitoring liver cancer. These strategies do not eliminate the need for monitoring, but they can make it much easier to manage the worry that comes with it. 

Evidence‑Based Coping Strategies 

  • Learn what monitoring is for and what results mean.
    People feel less anxious when they understand why tests are done and what different results mean. Clear explanations from health care providers, such as explaining that unclear or abnormal results do not always mean cancer, can reduce fear and stress (Hui et al., 2026). 
  • Ask direct questions during appointments.
    Questions like “What is this test checking for?” or “What happens if something looks different?” can help replace worry with facts and reduce uncertainty (Hui et al., 2026). 
  • Use mental health tools to manage worry.
    Research shows that cognitive behavioral therapy (CBT) and mindfulness practices help people notice anxious thoughts and calm their reactions. Simple steps such as deep breathing, guided relaxation, or focusing on the present moment can help during scan weeks (Low et al., 2025). 
  • Plan ahead for testing days.
    Having a plan helps people feel more in control. This may include scheduling something relaxing after an appointment, choosing a friend or family member to talk to, or limiting time spent searching online for alarming information (Low et al., 2025). 
  • Lean on social support.
    Talking with others who understand—such as support groups, patient programs, or trusted loved ones–can reduce feelings of isolation and anxiety. Feeling supported makes coping easier (Low et al., 2025). 
  • Treat mental health as part of liver health.
    Experts recommend screening for anxiety and depression as part of hepatitis B care. Counseling or emotional support can improve quality of life and help people stay engaged in important monitoring (Low et al., 2025). 

Studies show that even though monitoring can be stressful, most patients still want to continue because it helps save lives (Hui et al., 2026). The goal is not to stop testing, but to support emotional well‑being along the way. 

Liver cancer monitoring helps catch problems early, but living with constant check‑ups can be stressful. With clear information, mental health support and simple coping strategies, patients can stay connected to care while also protecting their well‑being. 

Baruch S. Blumberg Institute